Adeno-associated virus binding protein with improved alkali resistance

By introducing specific amino acid substitutions, AAV-binding proteins are made more resistant to alkali, ensuring effective and repeated use in AAV purification, thereby enhancing the efficiency of AAV vector production.

JP2024169303APending Publication Date: 2024-12-05TOSOH CORP
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024026427
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-02-26
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing AAV-binding proteins lack sufficient alkali resistance, making them ineffective for repeated use in alkaline washing during AAV purification processes.

Method used

The development of AAV-binding proteins with specific amino acid substitutions, such as replacing histidine at position 102 with tyrosine and valine at position 193 with threonine, enhances the proteins' alkali resistance, allowing them to withstand alkaline washing without losing binding activity.

Benefits of technology

The modified AAV-binding proteins demonstrate significantly improved alkali resistance, enabling repeated use in AAV purification and maintaining high purity, thus facilitating efficient industrial production of AAV vectors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169303000001_ABST
    Figure 2024169303000001_ABST
Patent Text Reader

Abstract

To provide improved adeno-associated virus (AAV) binding proteins with enhanced alkali resistance.SOLUTION: The foregoing problem is solved by substituting an amino acid residue at a specific position within the region corresponding to the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319 (UniProt No. Q8IZA0) with another specific amino acid residue.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a protein having binding activity to an adeno-associated virus (AAV), and more particularly to an improved AAV binding protein having improved alkali resistance. [Background technology]

[0002] Adeno-associated virus (AAV) is a non-enveloped virus classified in the Parvoviridae family and Dependovirus genus. The AAV envelope particle is composed of three types of proteins (VP1, VP2, and VP3), and is formed by mixing and assembling approximately 60 protein molecules in a ratio of VP1:VP2:VP3 = 1:1:10, resulting in a regular icosahedral shape with a diameter of 20 to 30 nm.

[0003] In nature, AAV lacks the ability to replicate autonomously, and its replication depends on helper viruses such as adenoviruses and herpes viruses. When the helper virus is present, the AAV genome replicates in the host cell, forming complete AAV particles containing the AAV genome, and the AAV particles are released from the host cell. On the other hand, when the helper virus is not present, the AAV genome is maintained in an episome or integrated into the host chromosome (latent state).

[0004] AAV is capable of infecting the cells of a wide range of species, including humans, and can also infect non-dividing cells that have completed differentiation, such as blood cells, muscles, and nerve cells. It is not pathogenic to humans, so there is little risk of side effects. In addition, the viral particles are physicochemically stable. For these reasons, AAV is attracting attention as a potential vector for gene transfer to treat congenital genetic diseases.

[0005] Recombinant AAV vectors (hereinafter simply referred to as "AAV vectors") are usually produced by introducing a nucleic acid encoding elements essential for AAV particle formation into cells to produce cells capable of producing AAV (hereinafter also referred to as AAV-producing cells), and then culturing the cells to express the elements essential for AAV particle formation. The produced AAV vector is recovered and purified from the AAV-producing cells to obtain a therapeutic AAV vector formulation.

[0006] As a method for recovering and purifying an AAV vector from an AAV-producing cell, there is a method using affinity chromatography based on the binding affinity with AAV, using an adsorbent containing an insoluble carrier and an AAV-binding protein immobilized on the carrier, which can recover and purify the AAV vector from a solution containing the AAV vector coexisting with impurities. As a specific example, Patent Document 1 uses a polypeptide containing the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0), but with amino acid residues at specific positions in these domains replaced with other amino acid residues, which has improved stability against heat, acid, and alkali, as an AAV-binding protein (hereinafter, also simply referred to as "ligand protein") immobilized on an insoluble carrier, thereby realizing high-purity purification of an AAV vector.

[0007] On the other hand, when the above-mentioned adsorbent is used for purification, after AAV purification, the remaining AAV and impurities are usually washed with an alkaline solution of high concentration (e.g., 0.1 M to 0.5 M) of sodium hydroxide. Therefore, it has been desired to create a ligand protein that can withstand such alkaline washing. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] WO2021 / 106882 issue Summary of the Invention [Problem to be solved by the invention]

[0009] As described above, the adeno-associated virus (AAV) binding protein used as a ligand protein in WO2021 / 106882 has improved stability against heat, acid, and alkali compared to the native type (AAV binding protein without amino acid substitution). On the other hand, a ligand protein that can withstand alkaline washing more than the AAV binding protein disclosed in the publication was required.

[0010] In other words, an object of the present invention is to provide an AAV binding protein that has improved alkali resistance compared to the AAV binding protein disclosed in the above publication. [Means for solving the problem]

[0011] In order to solve the above problems, the present inventors conducted intensive research and discovered that alkaline resistance can be significantly improved by substituting specific amino acid residues among the amino acid residues that constitute an adeno-associated virus (AAV) binding protein with other amino acid residues, thereby completing the present invention.

[0012] That is, the present invention includes the following aspects [1] to

[11] .

[0013] [1] An AAV binding protein selected from any one of the following (i) to (iii): (i) at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 2, provided that the amino acid residues from the 25th to the 213th At least one of the following amino acid residues (1) to (2) an AAV binding protein having an amino acid substitution and having AAV binding activity; (1) Substitution of histidine at position 102 of SEQ ID NO:2 with tyrosine (2) Substitution of valine at position 193 of SEQ ID NO:2 with threonine (ii) an AAV binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, with at least one of the amino acid substitutions (1) to (2) occurring in the amino acid residues at positions 25 to 213, and further comprising one or more of substitutions, deletions, insertions, and additions of one or more amino acid residues at one or more positions in addition to the amino acid substitutions shown in (1) to (2), and having AAV binding activity; (iii) An AAV binding protein comprising an amino acid sequence from serine at position 25 to aspartic acid at position 213 of the amino acid sequence set forth in SEQ ID NO: 2, which has an identity of 70% or more to the entire amino acid sequence in which at least one of the amino acid substitutions (1) and (2) has occurred, and in which the at least one of the amino acid substitutions remains, and which has AAV-binding activity.

[0014] [2] The AAV binding protein according to [1], further comprising at least one amino acid substitution as shown in (3) below: (3) Substitution of glutamine at position 180 of SEQ ID NO:2 with asparagine [3] The AAV binding protein according to [1] or [2], which contains at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, provided that at least any of the amino acid substitutions shown in (A) to (D) below occurs in the amino acid residues at positions 25 to 213, and has AAV binding activity; (A) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, histidine at position 102 of SEQ ID NO:2 is replaced with tyrosine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, alanine at position 174 of SEQ ID NO:2 is replaced with proline, glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine, and valine at position 193 of SEQ ID NO:2 is replaced with threonine. (B) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, valine at position 193 of SEQ ID NO:2 is substituted with threonine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (C) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, histidine at position 102 of SEQ ID NO:2 is substituted with tyrosine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (D) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, histidine at position 102 of SEQ ID NO:2 is substituted with tyrosine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, valine at position 193 of SEQ ID NO:2 is substituted with threonine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid.

[0015] [4] A polynucleotide encoding an AAV binding protein according to any one of [1] to [3].

[0016] [5] An expression vector comprising the polynucleotide described in [4].

[0017] [6] A transformant obtained by transforming Escherichia coli with the expression vector described in [5].

[0018] [7] A method for producing an AAV-binding protein, comprising the steps of expressing the AAV-binding protein by culturing the transformant described in [6], and recovering the expressed AAV-binding protein from the resulting culture.

[0019] [8] An AAV adsorbent comprising an insoluble carrier and an AAV binding protein described in any one of [1] to [3] immobilized on the carrier.

[0020] [9] A column containing the AAV adsorbent described in [8].

[0021]

[10] A method for purifying or analyzing AAV, comprising the steps of adding a solution containing AAV to the column described in [9] to adsorb the AAV to the adsorbent, and eluting the AAV adsorbed to the adsorbent using an elution solution.

[0022]

[11] The method for purifying or analyzing AAV described in

[10] , further comprising a step of washing the AAV adsorbent with an alkaline solution after the step of eluting AAV. Effect of the Invention

[0023] The adeno-associated virus (AAV) binding protein of the present invention is a protein in which amino acid residues at specific positions in the region corresponding to the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0) are replaced with other amino acid residues. The AAV binding protein of the present invention has significantly improved alkali resistance compared to conventional AAV binding proteins. Therefore, an AAV adsorbent having the AAV binding protein as a ligand can be washed with alkali and can be repeatedly used for AAV purification, making it useful for industrial production of AAV. [Brief description of the drawings]

[0024] [Figure 1] FIG. 1 shows the results of capturing AAV8 and eluting it under acidic conditions after immersing AVR27a-immobilized gel and POROS AAVX (manufactured by Thermo Fisher Scientific) in an alkaline solution for 24 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The present invention will be described in detail below.

[0026] As used herein, the AAV-binding protein refers to a protein that contains at least the amino acid residues from serine (S) at position 312 to aspartic acid (D) at position 500, which is a region corresponding to extracellular domain 1 (PKD1) and domain 2 (PKD2) in the amino acid sequence of KIAA0319L (UniProt No. Q8IZA0) set forth in SEQ ID NO: 1, which is a native AAV-binding protein, but in which an amino acid substitution has occurred at a specific position in the amino acid residues at positions 312 to 500.

[0027] In particular, the AAV binding protein may be selected from any of the following (i) to (iii): (i) at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 2, provided that the amino acid residues from the 25th to the 213th At least one of the following amino acid residues (1) to (2) an AAV binding protein having an amino acid substitution and having AAV binding activity; (1) Substitution of histidine at position 102 of SEQ ID NO:2 with tyrosine (2) Substitution of valine at position 193 of SEQ ID NO:2 with threonine (ii) an AAV binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, with at least one of the amino acid substitutions (1) to (2) occurring in the amino acid residues at positions 25 to 213, and further comprising one or more of substitutions, deletions, insertions, and additions of one or more amino acid residues at one or more positions in addition to the amino acid substitutions shown in (1) to (2), and having AAV binding activity; (iii) An AAV binding protein comprising an amino acid sequence from serine at position 25 to aspartic acid at position 213 of the amino acid sequence set forth in SEQ ID NO: 2, which has an identity of 70% or more to the entire amino acid sequence in which at least one of the amino acid substitutions (1) and (2) has occurred, and in which the at least one of the amino acid substitutions remains, and which has AAV-binding activity.

[0028] In (ii) above, "one or several" will vary depending on the position of the amino acid substitution in the three-dimensional structure of the AAV binding protein and the type of amino acid residue, but for example, it means any of the following: 1 to 50, 1 to 40, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1.

[0029] Examples of the substitutions, deletions, insertions, or additions described in (ii) above include the amino acid residue substitutions disclosed in WO2021 / 106882 and WO2023 / 140197.

[0030] In addition, the "substitution of one or several amino acid residues" in (ii) may include, in addition to the amino acid substitution at the specific position described above, a conservative substitution in which a substitution occurs between amino acids having similar physical and / or chemical properties. In the case of a conservative substitution, it is generally known to those skilled in the art that the function of a protein is maintained between a protein having a substitution and a protein having no substitution. Examples of conservative substitutions include substitutions between glycine and alanine, between serine and threonine, or between glutamic acid and aspartic acid (Protein Structure and Function, Medical Science International, 9, 2005). Another example of the amino acid substitution is a substitution for monomerizing the AAV binding protein of the present invention. Specifically, an amino acid substitution is an amino acid substitution in which a cysteine ​​residue that easily forms a higher-order structure is replaced with a serine residue or a methionine residue.

[0031] Furthermore, the "substitution, deletion, insertion, or addition of one or several amino acid residues" in (ii) above also includes naturally occurring mutations (mutants or variants) based on differences in the origin or species of the AAV binding protein.

[0032] The identity of the amino acid sequence in (iii) above may be 70% or more, and may be higher (e.g., 80% or more, 85% or more, 90% or more, or 95% or more). "Identity of amino acid sequence" refers to identity with respect to the entire amino acid sequence. "Identity" between amino acid sequences refers to the ratio of amino acid residues in those amino acid sequences that have the same type of amino acid (Experimental Medicine, 31(3), Yodosha). The identity of amino acid sequences can be determined using an alignment program such as BLAST (Basic Local Alignment Search Tool) or FASTA.

[0033] The AAV-binding protein of the present invention may include all or a part of other extracellular region domains (domain 3 (PKD3), domain 4 (PKD4) and domain 5 (PKD5)) located on the C-terminus of the protein, may include all or a part of a signal sequence or cysteine-rich region such as the MANSC (Motif At N terminus with Seven Cysteines) domain located on the N-terminus of PKD1, or may include all or a part of a transmembrane region and an intracellular region located on the N-terminus and / or C-terminus of the extracellular region.

[0034] Specifically, the amino acid substitution at the specific position includes at least the amino acid residues from the 312th serine to the 500th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 1, provided that in the amino acid residues from the 312th to the 500th It is preferable that the polypeptide contains at least the amino acid substitutions V317D (this notation indicates that the 317th valine in SEQ ID NO: 1 has been substituted with aspartic acid, and the same applies below), N324H, V326A, A330V, Q334L, E335V, T341A, Y342S, K362E, K371N, F379Y, K380R, V381A, I382V, G390S, K399E, S476R, S482T, N487D, and N492D, and also contains at least one amino acid substitution of H389Y and V480T, as this improves stability against alkali. Furthermore, if the amino acid substitutions H389Y and / or V480T also include the amino acid substitution K(Q)467N (this notation indicates that the 467th lysine in SEQ ID NO: 1 is first replaced by glutamine in SEQ ID NO: 2 and then further replaced by asparagine, the same applies below), this is more preferable since it further improves the stability against heat and alkali.

[0035] In addition, an AAV binding protein consisting of amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid substitutions V317D, N324H, V326A, A330V, Q334L, E335V, T341A, Y342S, K362E, K371N, F379Y, K380R, V381A, I382V, G390S, K399E, K467Q, S476R, S482T, N487D, and N492D have occurred in the amino acid residues from position 312 to position 500, is synonymous with an AAV binding protein consisting of amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2. The positions of the amino acid residues in SEQ ID NO: 2 correspond to the positions of the amino acid residues in SEQ ID NO: 1 minus 287. Specifically, the H389Y amino acid substitution corresponds to the substitution of the amino acid residue located at position 102 in SEQ ID NO:2, and the V480T amino acid substitution corresponds to the substitution of the amino acid residue located at position 193 in SEQ ID NO:2.

[0036] In the AAV-binding protein of the present invention, the number of amino acids to be substituted is not particularly limited. Examples include the AAV-binding proteins shown in (A) to (D) below. These AAV-binding proteins are more preferred in terms of improved stability to alkali.

[0037] (A) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, and having at least the following amino acid substitutions in the amino acid residues from position 25 to position 213: N329K (this notation indicates that asparagine at position 329 in SEQ ID NO:1 (position 42 in SEQ ID NO:2) has been substituted with lysine; the same applies below), H389Y, E401G, T426A, A461P, K(Q)467N, and V480T.

[0038] (B) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, and having at least the following amino acid substitutions in the amino acid residues at positions 25 to 213: N329K, I366F, V394A, E401G, T426A, K455R, A461P, K(Q)467N, V480T, and K497E.

[0039] (C) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, and having at least the following amino acid substitutions in the amino acid residues at positions 25 to 213: N329K, I366F, H389Y, V394A, E401G, T426A, K455R, A461P, K(Q)467N, and K497E.

[0040] (D) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, and having at least the following amino acid substitutions in the amino acid residues at positions 25 to 213: N329K, I366F, H389Y, V394A, E401G, T426A, K455R, A461P, K(Q)467N, V480T, and K497E.

[0041] The protein of the present invention may be an AAV-binding protein selected from any of the following (iv) to (vi): (iv) An AAV binding protein comprising at least the amino acid sequence set forth in SEQ ID NO: 29, 32, 33, 38, 43, 44 or 45. (v) an AAV binding protein having an amino acid sequence set forth in SEQ ID NO: 29, 32, 33, 38, 43, 44 or 45, which contains any one or more of substitutions, deletions, insertions and additions of one or several amino acid residues at one or several positions, with the proviso that certain mutations are maintained, and which has AAV binding activity; (vi) An AAV binding protein having an amino acid sequence that has 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 29, 32, 33, 38, 43, 44 or 45, with the proviso that certain mutations are maintained, and having AAV binding activity.

[0042] The AAV-binding protein of the present invention may further have an oligopeptide attached to its N-terminus or C-terminus that is useful for separating the AAV-binding protein from a solution in the presence of contaminants. Examples of the oligopeptide include polyhistidine, polylysine, polyarginine, polyglutamic acid, polyaspartic acid, etc. In addition, an oligopeptide containing cysteine ​​that is useful for immobilizing the AAV-binding protein of the present invention on a solid phase such as a chromatographic support may further be attached to the N-terminus or C-terminus of the AAV-binding protein of the present invention.

[0043] The length of the oligopeptide added to the N- or C-terminus of the AAV-binding protein is not particularly limited as long as it does not impair the AAV-binding ability or stability of the AAV-binding protein of the present invention. When adding the oligopeptide to the AAV-binding protein of the present invention, a polynucleotide encoding the oligopeptide may be prepared and then added to the N- or C-terminus of the AAV-binding protein by genetic engineering using a method well known to those skilled in the art, or a chemically synthesized oligopeptide may be chemically bonded to the N- or C-terminus of the AAV-binding protein of the present invention.

[0044] Furthermore, a signal peptide may be added to the N-terminus of the AAV-binding protein of the present invention to promote efficient expression in Escherichia coli used as a host. Examples of the signal peptide include signal peptides that cause proteins to be secreted into the periplasm, such as PelB, OmpA, DsbA, DsbC, MalE, and TorT (JP Patent Publication No. 2011-097898). It is not necessary to add a signal peptide to the N-terminus. This is preferable in that the homogeneity of the protein is improved during protein preparation.

[0045] As an example of a method for producing a polynucleotide encoding the AAV binding protein of the present invention (hereinafter also referred to as "polynucleotide of the present invention"), (I) A method of converting the amino acid sequence of the AAV binding protein of the present invention into a nucleotide sequence and artificially synthesizing a polynucleotide containing the nucleotide sequence; (II) A method in which a polynucleotide containing the entire or partial sequence of an AAV-binding protein is prepared artificially directly or from the cDNA of the AAV-binding protein using a DNA amplification method such as PCR, and the prepared polynucleotides are then ligated by an appropriate method.

[0046] In the above method (I), when converting an amino acid sequence to a nucleotide sequence, it is preferable to convert the sequence taking into consideration the frequency of codon usage in Escherichia coli, the host to be transformed. Specifically, AGA / AGG / CGG / CGA for arginine (R), ATA for isoleucine (I), CTA for leucine (L), GGA for glycine (G), and CCC for proline (P) are used infrequently (so-called rare codons), so conversion should be performed to avoid these codons. Analysis of the frequency of codon usage can also be performed by using public databases (for example, the Codon Usage Database on the website of the Kazusa DNA Research Institute).

[0047] When introducing a mutation into the polynucleotide of the present invention, an error-prone PCR method can be used. The reaction conditions in the error-prone PCR method are not particularly limited as long as they are conditions that allow the introduction of a desired mutation into the polynucleotide encoding the AAV binding protein. For example, the concentrations of the four types of substrate deoxynucleotides (dATP / dTTP / dCTP / dGTP) are made non-uniform, and MnCl2 is added to the PCR reaction solution at a concentration of 0.01 mM to 10 mM (preferably 0.1 mM to 1 mM) to perform PCR, thereby introducing a mutation into the polynucleotide. In addition, as a method for introducing a mutation into a polynucleotide other than the error-prone PCR method, a method of introducing a mutation into a polynucleotide by contacting and acting a mutagenic agent on a polynucleotide containing the entire or partial sequence of the AAV binding protein or irradiating it with ultraviolet light can be mentioned. In this method, as a mutagen used as a mutagen, mutagenic agents commonly used by those skilled in the art, such as hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine, nitrous acid, sulfurous acid, and hydrazine, may be used.

[0048] When transforming a host, E. coli, with the polynucleotide of the present invention, the polynucleotide of the present invention itself may be used, but it is more preferable to use an expression vector (e.g., a bacteriophage, cosmid, or plasmid usually used for transforming prokaryotic or eukaryotic cells) into which the polynucleotide of the present invention has been inserted at an appropriate position. The expression vector is not particularly limited as long as it is stable in the host (E. coli) to be transformed and can be replicated, and examples of the expression vector include pET plasmid vector, pUC plasmid vector, pTrc plasmid vector, and pCDF plasmid vector.

[0049] The appropriate position means a position that does not disrupt the replication function of the expression vector, the desired antibiotic marker, or the region involved in transduction. When inserting the polynucleotide of the present invention into the expression vector, it is preferable to insert it in a state where it is linked to a functional polynucleotide such as a promoter required for expression. Examples of such promoters include the trp promoter, tac promoter, trc promoter, lac promoter, T7 promoter, recA promoter, and lpp promoter.

[0050] The host Escherichia coli can be transformed with the expression vector into which the polynucleotide of the present invention is inserted, prepared by the above-mentioned method (hereinafter, also simply referred to as "the expression vector of the present invention"), by a method commonly used by those skilled in the art. Specifically, transformation can be performed by a method described in a known document such as Molecular Cloning (Cold Spring Harbor Laboratory), 256, 1992. The transformants obtained by transformation by the above-mentioned method can be screened by an appropriate method to obtain a transformant capable of expressing the AAV binding protein of the present invention (hereinafter, also simply referred to as "the transformant of the present invention").

[0051] To prepare the expression vector of the present invention from the transformant of the present invention, it may be prepared from the culture obtained by culturing the transformant of the present invention by alkaline extraction or using a commercially available extraction kit such as QIAprep Spin Miniprep kit (Qiagen).

[0052] The AAV-binding protein of the present invention can be produced by culturing the transformant of the present invention and recovering the AAV-binding protein of the present invention from the resulting culture. In this specification, the culture includes not only the cultured cells of the transformant of the present invention themselves, but also the medium used for the culture.

[0053] The transformant used in the protein production method of the present invention may be cultured in a medium suitable for culturing the target host (Escherichia coli), and a preferred example of the medium is LB (Luria-Bertani) medium supplemented with necessary nutrient sources. In order to selectively grow the transformant of the present invention depending on whether or not the vector of the present invention has been introduced, it is preferable to culture the transformant by adding a drug corresponding to the drug resistance gene contained in the vector to the medium. For example, if the vector contains a kanamycin resistance gene, kanamycin may be added to the medium.

[0054] In addition to carbon, nitrogen and inorganic salt sources, the medium may contain an appropriate nutrient source, and may contain one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate and dithiothreitol, if desired. The culture temperature is generally 10°C to 40°C, preferably 20°C to 37°C, more preferably around 25°C, but may be selected depending on the characteristics of the protein to be expressed. The pH of the medium is pH 6.8 to 7.4, preferably around pH 7.0. When the vector of the present invention contains an inducible promoter, it is preferable to induce it under conditions that allow good expression of the AAV binding protein of the present invention.

[0055] An example of an inducer is IPTG (isopropyl-β-D-thiogalactopyranoside). The turbidity of the culture solution (absorbance at 600 nm) is measured, and when it reaches approximately 0.5 to 1.0, an appropriate amount of IPTG is added, followed by continued cultivation, to induce expression of the AAV binding protein. The concentration of IPTG added may be appropriately selected from the range of 0.005 mM to 1.0 mM, with the range of 0.01 mM to 0.5 mM being preferred. Various conditions for IPTG induction may be those well known in the art.

[0056] To recover the AAV-binding protein of the present invention from a culture obtained by culturing the transformant of the present invention, the AAV-binding protein of the present invention may be recovered by separating / purifying it from the culture using a method suitable for the expression form of the AAV-binding protein of the present invention in the transformant of the present invention. For example, when the protein is expressed in the culture supernatant, the cells may be separated by centrifugation, and the AAV-binding protein of the present invention may be purified from the resulting culture supernatant. When the protein is expressed intracellularly (including the periplasm), the cells may be collected by centrifugation, disrupted by adding an enzyme treatment agent, a surfactant, or the like, and the AAV-binding protein of the present invention may be extracted and then purified.

[0057] The AAV-binding protein of the present invention can be purified by any method known in the art, including, for example, separation / purification using liquid chromatography, which includes ion exchange chromatography, hydrophobic interaction chromatography, gel filtration chromatography, affinity chromatography, etc., and the AAV-binding protein of the present invention can be prepared at a high purity by performing a purification procedure using a combination of these chromatographies.

[0058] The binding activity of the obtained AAV-binding protein of the present invention to AAV can be measured, for example, by using an enzyme-linked immunosorbent assay (hereinafter referred to as ELISA) or a surface plasmon resonance method. The AAV used to measure the binding activity may be an AAV vector or a VLP (virus-like particle). In addition, any serotype (serum type) of AAV vector and VLP may be used as long as they exhibit binding activity to the AAV-binding protein of the present invention.

[0059] The AAV-binding protein of the present invention can be used, for example, for the purification or analysis of AAV. When used for this purpose, there is no particular limitation on the AAV to be bound, and it may be an AAV that exists in nature or an AAV that is artificially produced. Examples of AAV that exists in nature include serotype 1 (AAV1), serotype 2 (AAV2), serotype 3 (AAV3), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype 9 (AAV9), serotype 10 (AAV10), serotype 11 (AAV11), serotype 12 (AAV12), and serotype 13 (AAV13). Examples of artificially produced AAV include AAVrh8, AAVrh10, and chimeric AAVs that have the characteristics (cell tropism and infectivity) of two or more of these serotypes.

[0060] The AAV-binding protein of the present invention can be used, for example, by immobilizing it on an insoluble carrier. That is, the purification or analysis of AAV can be specifically carried out, for example, using an AAV adsorbent comprising an insoluble carrier and the AAV-binding protein of the present invention immobilized on the insoluble carrier. In this specification, an AAV adsorbent comprising an insoluble carrier and the AAV-binding protein of the present invention immobilized on the insoluble carrier is also referred to as the AAV adsorbent of the present invention. Note that the purification of AAV is not limited to the purification of AAV from a solution containing impurities, but also includes the purification of AAV based on the structure, properties, activity, etc. There are no limitations on the material, shape, etc. of the insoluble carrier, and an example is the insoluble carrier disclosed in WO2021 / 106882. In addition, the insoluble carrier may be porous or non-porous.

[0061] The AAV binding protein of the present invention can be immobilized on an insoluble carrier, for example, via a covalent bond. Specifically, the AAV binding protein of the present invention can be immobilized on an insoluble carrier, for example, by covalently binding the AAV binding protein of the present invention to an insoluble carrier via an active group possessed by the insoluble carrier. The immobilization of the AAV binding protein of the present invention on an insoluble carrier may be carried out, for example, based on the disclosure in WO2021 / 106882.

[0062] The AAV adsorbent of the present invention can be used, for example, in the purification or analysis of AAV by packing it into a column. Specifically, for example, a solution containing AAV is added to a column packed with the AAV adsorbent of the present invention (hereinafter also simply referred to as the "column of the present invention") to adsorb the AAV to the adsorbent, and the AAV adsorbed to the adsorbent is eluted, thereby purifying or analyzing AAV. That is, the present invention provides a method for purifying or analyzing AAV, which includes, for example, a step of adding a solution containing AAV to the column of the present invention to adsorb the AAV to the adsorbent, and a step of eluting the AAV adsorbed to the adsorbent. Purification of AAV using the column of the present invention may be carried out, for example, based on the disclosure in WO2021 / 106882.

[0063] By carrying out the purification of AAV using the AAV adsorbent of the present invention, for example, purified AAV can be obtained. That is, in one embodiment, the purification method of AAV may be a method for producing AAV, specifically, a method for producing purified AAV. AAV is obtained, for example, as an eluted fraction containing AAV. That is, a fraction containing eluted AAV can be separated. Separation of the AAV fraction can be performed, for example, by a conventional method. Methods for separating the AAV fraction include a method of replacing the collection container at regular intervals or at regular volumes, a method of replacing the collection container according to the shape of the chromatogram of the eluate, and a method of separating the fraction using an automatic fraction collector such as an autosampler. Furthermore, AAV can be recovered from a fraction containing AAV. Recovery of AAV from a fraction containing AAV can be performed, for example, by a known method used for protein purification.

[0064] By carrying out alkaline washing using the AAV adsorbent of the present invention, for example, it is possible to prevent the inclusion of remaining AAV or impurities. That is, in one embodiment, the method for washing AAV may be a method for washing AAV, specifically, an alkaline washing method after purification. In addition, since the AAV binding protein of the present invention is also acid-resistant, it may be a method of washing with a low pH solution and then alkaline washing. An example of the alkaline solution used for washing is an aqueous solution of sodium hydroxide at 0.1 M or more and 0.5 M or less. EXAMPLES

[0065] The present invention will be described in more detail below using examples and reference examples, but the present invention is not limited to these examples. Note that the reference examples do not constitute the present invention.

[0066] Example 1 Preparation of VLP2 (1) The E. coli JM109 strain was transformed with the plasmid pRC2-mi342 Vector (Takara Bio) and pHelper Vector (Takara Bio), which contain a polynucleotide encoding the capsid of AAV serotype 2 (AAV2). The resulting transformant was shake-cultured overnight at 37°C in a 5-L baffled flask containing 1 L of 2xYT medium (1.6% (w / v) tryptone, 1% (w / v) yeast extract, 0.5% (w / v) sodium chloride) containing 100 μg / mL carbenicillin.

[0067] (2) The culture medium of (1) was centrifuged to recover the bacterial cells, and then the pRC2-mi342 Vector and pHelper Vector were prepared in large quantities from the recovered bacterial cells using a Plasmid Mega Kit (Qiagen).

[0068] (3) HEK293T cells were cultured in five T-225 flasks (Thermo Fisher Scientific) containing 40 mL of D-MEM medium (Fujifilm Wako Pure Chemical Industries, Ltd.) containing 10% (v / v) bovine serum.

[0069] (4) Using TransIT-ViruGEN Transfection Reagent (Takara Bio), the pRC2-mi342 Vector and pHelper Vector prepared in (2) were transfected into the HEK293T cells cultured in (3), and the cells were cultured statically for 3 days under conditions of 5% carbon dioxide and 37°C.

[0070] (5) The cells cultured in (4) were collected and extracted and purified using the AAVpro Purification Kit (Takara Bio Inc.) to obtain VLP2 (virus-like particle, outer protein particle of AAV serotype 2). Approximately 1 mL of VLP2 purified solution was prepared from five T-225 flasks.

[0071] Reference Example 1: Preparation and screening of a mutation library for AAV binding protein AVR21 Using vector pET-AVR21 capable of expressing a polypeptide (SEQ ID NO: 2) containing the AAV binding protein AVR21 as a template, random mutations were introduced into the polynucleotide portion encoding the protein by error-prone PCR. In the polypeptide consisting of the amino acid sequence described in SEQ ID NO: 2, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide (the 22 amino acid residues on the N-terminal side of UniProt No. P0C1C1), the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR21, and the portion from the 214th to the 219th histidine (H) is the tag sequence. AVR21 is a polypeptide in which the following 21 amino acid substitutions have been made in the amino acid residues from position 312 to position 500 of SEQ ID NO: 1, which correspond to extracellular domain 1 (PKD1) and domain 2 (PKD2) of the natural AAV-binding protein KIAA0319L (UniProt No. Q8IZA0) (WO2023 / 140197). Valine (V) at position 317 of SEQ ID NO:1 (position 30 of SEQ ID NO:2) is replaced with aspartic acid (D) Asparagine (N) at position 324 of SEQ ID NO:1 (position 37 of SEQ ID NO:2) is substituted with histidine (H) Valine (V) at position 326 of SEQ ID NO:1 (position 39 of SEQ ID NO:2) is substituted with alanine (A) Alanine (A) at position 330 of SEQ ID NO:1 (position 43 of SEQ ID NO:2) is replaced with valine (V). The glutamine (Q) at position 334 of SEQ ID NO:1 (position 47 of SEQ ID NO:2) is replaced with leucine (L) Glutamic acid (E) at position 335 of SEQ ID NO:1 (position 48 of SEQ ID NO:2) is replaced with valine (V) Threonine (T) at position 341 of SEQ ID NO:1 (position 54 of SEQ ID NO:2) is replaced with alanine (A) Tyrosine (Y) at position 342 of SEQ ID NO:1 (position 55 of SEQ ID NO:2) is substituted with serine (S). Lysine (K) at position 362 of SEQ ID NO:1 (position 75 of SEQ ID NO:2) is substituted with glutamic acid (E) Lysine (K) at position 371 of SEQ ID NO:1 (position 84 of SEQ ID NO:2) is substituted with asparagine (N) Phenylalanine (F) at position 379 of SEQ ID NO:1 (position 92 of SEQ ID NO:2) is replaced with tyrosine (Y) Lysine (K) at position 380 of SEQ ID NO:1 (position 93 of SEQ ID NO:2) is substituted with arginine (R) Valine (V) at position 381 of SEQ ID NO:1 (position 94 of SEQ ID NO:2) is replaced with alanine (A) Isoleucine (I) at position 382 of SEQ ID NO:1 (position 95 of SEQ ID NO:2) is substituted with valine (V) Glycine (G) at position 390 of SEQ ID NO:1 (position 103 of SEQ ID NO:2) is replaced with serine (S) Lysine (K) at position 399 of SEQ ID NO:1 (position 112 of SEQ ID NO:2) is substituted with glutamic acid (E) Lysine (K) at position 467 of SEQ ID NO:1 (position 180 of SEQ ID NO:2) is replaced with glutamine (Q) Serine (S) at position 476 of SEQ ID NO:1 (position 189 of SEQ ID NO:2) is replaced with arginine (R) The serine (S) at position 482 of SEQ ID NO:1 (position 195 of SEQ ID NO:2) is replaced with threonine (T). Asparagine (N) at position 487 of SEQ ID NO:1 (position 200 of SEQ ID NO:2) is replaced with aspartic acid (D) Asparagine (N) at position 492 of SEQ ID NO: 1 (position 205 of SEQ ID NO: 2) is substituted with aspartic acid (D).

[0072] (1) Error-prone PCR was performed using vector pET-AVR21 capable of expressing a polypeptide (SEQ ID NO: 2) containing AVR21 as a template. Error-prone PCR was performed by preparing a reaction solution having the composition shown in Table 1, heat-treating the reaction solution at 98°C for 2 minutes, and carrying out 30 cycles of reaction in which one cycle consisted of a first step at 98°C for 30 seconds, a second step at 55°C for 20 seconds, and a third step at 72°C for 90 seconds, and finally heat-treating the reaction at 72°C for 5 minutes. Mutations were successfully introduced into the polynucleotide encoding the AAV binding protein by the error-prone PCR, and the average mutation introduction rate was 1.4 amino acid mutations per molecule.

[0073] [Table 1]

[0074] (2) The PCR product obtained in (1) was purified and then digested with the restriction enzymes NcoI and XhoI, and ligated into the expression vector pET26b (Merck Millipore) that had been previously digested with the same restriction enzymes.

[0075] (3) After the ligation reaction was completed, the reaction mixture was used to transform E. coli BL21(DE3) and the resulting mixture was cultured on a Luria-Bertani (LB) plate medium containing 50 μg / mL kanamycin (37°C for 18 hours). The colonies formed on the plate were used as a random mutant library.

[0076] (4) The random mutant library (transformants) prepared in (3) was inoculated into 200 μL of 2xYT liquid medium containing 50 μg / mL kanamycin, and cultured overnight at 37°C with shaking in a 96-well deep well plate.

[0077] (5) The culture medium from (4) was centrifuged, and the resulting culture supernatant was diluted 2-fold with ultrapure water. 60 μL of the diluted culture medium was mixed with 60 μL of 0.5 M sodium hydroxide aqueous solution and subjected to an alkali treatment at 30° C. for 30 minutes.

[0078] (6) The binding activity of the AAV binding protein to VLP2 when treated with (5) and when not treated with (5) was evaluated by the ELISA (Enzyme-Linked Immunosorbent Assay) method described below.

[0079] (6-1) The VLP2 prepared in Example 1 was diluted 200-fold with 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride, added to a 96-well microplate (Thermo Fisher Scientific) at 100 μL / well, and immobilized (at 4° C. for 18 hours). After immobilization, the plate was blocked with 2% (w / v) SKIM MILK (Becton Dickinson) and 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride.

[0080] (6-2) After washing the wells with a washing buffer (20 mM Tris-HCl buffer (pH 7.4) containing 0.05% (w / v) Tween 20 (Sigma-Aldrich) and 150 mM sodium chloride), the culture supernatant prepared in (3) was added and the AAV binding protein was reacted with VLP2 (at 30°C for 1 hour).

[0081] (6-3) After the reaction was completed, the plate was washed with the washing buffer, and an Anti-6His antibody (manufactured by Bethyl Laboratories) diluted to 100 ng / mL was added at 100 μL / well.

[0082] (6-4) After reacting at 30°C for 1 hour and washing with the washing buffer, TMB Peroxidase Substrate (KPL) was added at 50 μL / well. Color development was stopped by adding 50 μL / well of 1 M phosphoric acid, and the absorbance at 450 nm was measured using a microplate reader (Tecan).

[0083] The residual activity was calculated by dividing the binding activity between the AAV binding protein and VLP2 when alkali treatment was performed by the binding activity between the AAV binding protein and VLP2 when alkali treatment was not performed.

[0084] (7) A random mutant library of about 1,800 strains was evaluated using the method of (6), and transformants expressing AAV binding proteins with improved residual activity compared to the parent molecule AVR21 were selected from the library. The selected transformants were cultured, and expression vectors were prepared using a QIAprep Spin Miniprep kit (Qiagen).

[0085] (8) The sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed using a fully automated DNA sequencer, Genetic Analyzer 3500 (Thermo Fisher Scientific), to identify the amino acid substitution sites. In this analysis, an oligonucleotide consisting of the sequence shown in SEQ ID NO: 3 (5'-TAATACgACTCACTATAggg-3') or SEQ ID NO: 4 (5'-ATgCTAgTTATTgCTCAgCgg-3') was used as a sequencing primer.

[0086] Table 2 shows the amino acid substitution positions relative to AVR21 of the AAV binding proteins expressed by the transformants selected in (7) above, as well as the residual activity [%] after alkali treatment.

[0087] In the amino acid sequence of SEQ ID NO:2, from the 25th serine (S) to the 213th aspartic acid (D), the following amino acids are selected from the group consisting of I319N (this notation indicates that the isoleucine at the 319th position in SEQ ID NO:1 (the 32nd position in SEQ ID NO:2) is replaced with asparagine, and the same applies below), L321Q, L328P, N329K, N329S, V332A, E(V)335A (this notation indicates that the glutamic acid at the 335th position in SEQ ID NO:1 (the 48th position in SEQ ID NO:2) is replaced with valine in SEQ ID NO:2, and then replaced with alanine, and the same applies below), K338R, E340G, T343A, T343S, Y344F, D345G, and Q347K. , T350A, E360D, Q365R, I366F, L367P, K368R, L369S, K(N)371D, K(N)371S, L376P, Y377F, Y377N, E378G, F(Y)379S, V(A)381T, I(V)382I, E384D, H389R, V394A, V394I, V396E, T397A AAV binding proteins having at least one of the following amino acid substitutions, T397S, E401G, P402S, V412A, T426A, D435A, E453D, E454D, A461P, S466T, N472K, K497E, and D500N, can be said to have improved alkaline stability compared to AVR21.

[0088] [Table 2]

[0089] Reference Example 2: Preparation and screening of a mutation library for the AAV binding protein AVR8g Using vector pET-AVR8g capable of expressing a polypeptide containing the AAV binding protein AVR8g (SEQ ID NO: 23) as a template, random mutations were introduced into the polynucleotide portion encoding the protein by error-prone PCR. In the polypeptide consisting of the amino acid sequence described in SEQ ID NO: 23, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR8g, and the portion from the 214th to the 219th histidine (H) is the tag sequence. AVR8g is also a polypeptide in which the amino acid substitutions V317D, Y342C, K362E, K371N, G390S, K399E, S476R and N487D have been made in the amino acid residues 312 to 500 of SEQ ID NO: 1, which correspond to the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0) (WO2021 / 106882).

[0090] (1) Error-prone PCR was performed in the same manner as in Reference Example 1(1) except that the plasmid pET-AVR8g, into which a polynucleotide (SEQ ID NO: 24) encoding AVR8g (SEQ ID NO: 23) was inserted, was used as a template and the concentration of the template was 10 ng / μL. Mutations were introduced into the polynucleotide encoding AVR8g by the error-prone PCR, and the average mutation introduction rate was 2.3 amino acid mutations per molecule.

[0091] (2) The PCR products obtained in (1) were purified, and then a random mutant library was prepared by the methods described in Reference Example 1 (2) and (3).

[0092] (3) The random mutant library (transformants) prepared in (2) was inoculated into 200 μL of 2xYT liquid medium containing 50 μg / mL kanamycin, and cultured overnight at 37°C with shaking in a 96-well deep-well plate.

[0093] (4) 10 μL of the culture medium prepared in (3) was transferred to 500 μL of 2xYT liquid medium containing 0.1 mM IPTG (IsoPropyl-β-D-ThioGalactopyranoside) and 50 μg / mL kanamycin, and further cultured overnight at 25°C with shaking using a 96-well deep well plate.

[0094] (5) The culture supernatant obtained by centrifuging the culture medium in (4) was diluted 16-fold with ultrapure water. 60 μL of the diluted culture supernatant was mixed with 60 μL of 0.1 M glycine sodium hydroxide buffer (pH 10.0) and subjected to heat and alkali treatment at 51.3° C. for 15 minutes.

[0095] (6) Binding activity of AAV binding protein to VLP2 after treatment in (5) The binding activity between the AAV binding protein and VLP2 in the absence of the treatment in (5) was measured by the ELISA method described in Reference Example 1 (6).

[0096] The residual activity was calculated by dividing the binding activity of the AAV binding protein to VLP2 when heat treatment was performed by the binding activity of the AAV binding protein to VLP2 when heat treatment was not performed.

[0097] (7) A random mutant library of about 1,800 strains was evaluated by the method described in (6), and transformants expressing AAV binding proteins with improved residual activity compared to the parent molecule AVR8g were selected from the library. The selected transformants were cultured, and expression vectors were prepared using a QIAprep Spin Miniprep kit (Qiagen).

[0098] (8) The sequence of the polynucleotide region encoding the AAV binding protein inserted into the obtained expression vector was analyzed by the method described in Reference Example 1(8) to identify the amino acid substitution sites.

[0099] The amino acid substitution positions relative to AVR8g and the residual activity [%] after heat and alkali treatment of the AAV binding proteins expressed by the transformants selected in (7) above are summarized in Table 3. As can be seen from Table 3, the residual activity after heat and alkali treatment was improved compared to AVR8g due to the four amino acid substitutions, Y331H, F379S, K467N, and A491T.

[0100] [Table 3]

[0101] Reference Example 3: Evaluation of alkaline stability of AVR8g amino acid substituted derivatives It was confirmed whether the thermal and alkaline stability would be improved by introducing any one of the amino acid substitutions (Y331H, F379S, K467N, and A491T) involved in improving the thermal and alkaline stability of AAV binding proteins, as clarified in Reference Example 2, into AVR8g (SEQ ID NO: 23). Specifically, the thermal and alkaline stability of the following four types of AAV binding proteins (a) to (d) was confirmed. (a) A protein in which the amino acid substitution Y331H has been introduced into AVR8g (SEQ ID NO: 25, named AVR9a) (b) A protein in which the amino acid substitution F379S has been introduced into AVR8g (SEQ ID NO: 26, named AVR9b) (c) A protein in which the amino acid substitution K467N has been introduced into AVR8g (SEQ ID NO: 27, named AVR9c) (d) A protein in which the amino acid substitution A491T has been introduced into AVR8g (SEQ ID NO: 28, named AVR9d) (1) A transformant (host: Escherichia coli BL21 strain (DE3)) capable of expressing any one of AVR9a (SEQ ID NO: 25), AVR9b (SEQ ID NO: 26), AVR9c (SEQ ID NO: 27), and AVR9d (SEQ ID NO: 28) was inoculated into 3 mL of 2xYT liquid medium containing 50 μg / mL kanamycin, and pre-cultured overnight at 37°C under aerobic shaking.

[0102] (2) 2 mL of the preculture solution from (1) was inoculated into 200 mL of 2xYT liquid medium containing 50 μg / mL kanamycin in a 500 mL baffled flask, and cultured aerobically at 37°C with shaking.

[0103] (3) After 2.0 hours from the start of the culture, the mixture was cooled on ice, IPTG was added to a final concentration of 0.1 mM, and the mixture was subsequently cultured aerobically with shaking at 25°C for 20 hours.

[0104] (4) After the cultivation was completed, the culture medium was centrifuged at 4°C and 8,000 rpm for 20 minutes to recover each bacterial cell.

[0105] (5) The cells collected in (4) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution A") at 5 mL / 1 g (cells), and then disrupted using an ultrasonic generator (Insonator 201M [Kubota Shoji Co., Ltd.]) at 4°C for about 10 minutes at an output of about 150 W. The disrupted cell solution was centrifuged twice at 8000 rpm for 20 minutes at 4°C, and each supernatant was collected.

[0106] (6) The supernatant obtained in (5) was applied to an open column packed with 1.5 mL of Ni Sepharose 6 Fast Flow (manufactured by Cytiva) that had been previously equilibrated with equilibration solution A. After washing with equilibration solution A, the column was eluted with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.

[0107] (7) Each eluate obtained in (6) was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride to prepare an AAV-binding protein.

[0108] (8) The binding activity of the AAV-binding protein prepared in (7) to the VLP2 prepared in Example 1 was measured using the ELISA method described in Reference Example 1 (6). Based on the absorbance at 450 nm, which is the measurement result, the AAV-binding protein obtained in (7) was diluted with pure water so that the measured value would be similar.

[0109] (9) 60 μL of the diluted AAV binding protein solution was mixed with 60 μL of 0.1 M glycine sodium hydroxide buffer (pH 10.0) and subjected to heat and alkali treatment at 55.7° C., 60.1° C., 66.1° C., or 70° C. for 15 minutes.

[0110] (10) Binding activity of AAV binding protein to VLP2 after treatment in (9) and the binding of AAV binding protein to VLP2 without the treatment of (9). The combined activity was measured by the ELISA method described in Reference Example 1(6). The residual activity was calculated by dividing the binding activity between the AAV binding protein and VLP2 after the treatment in (9) was performed by the binding activity between the AAV binding protein and VLP2 without the heat treatment in (9).

[0111] The results are shown in Table 4. It can be said that an AAV binding protein having at least one amino acid substitution, Y331H, F379S, K467N, or A491T, in the amino acid residues from serine (S) at position 25 to aspartic acid (D) at position 213 in the amino acid sequence of AVR8g (SEQ ID NO: 29) has improved heat and alkali stability compared to AVR8g.

[0112] [Table 4]

[0113] Example 2: Preparation of AVR21 Amino Acid Substitution Aggregates Among the amino acid substitutions involved in improving the alkaline stability of the AAV binding protein clarified in Reference Example 1, N329K, E401G, T426A, and A461P were selected, and among the amino acid substitutions involved in improving the heat and alkaline stability of the AAV binding protein clarified in Reference Examples 2 and 3, K467N, H389Y, and V480T were selected, and these amino acid substitutions were accumulated in AVR21 (SEQ ID NO: 2) to further improve the alkaline stability. Specifically, two types of AAV binding proteins shown in (a) and (b) below were designed and prepared. (a) An AAV binding protein having amino acid substitutions of N329K, E401G, T426A, and A461P introduced into AVR21 (SEQ ID NO: 5, designated AVR25a) (b) An AAV binding protein having the following amino acid substitutions introduced into AVR21: N329K, H389Y, E401G, T426A, A461P, K(Q)467N, and V480T (SEQ ID NO: 6; designated AVR27a) Hereinafter, methods for producing the two types of AAV binding proteins shown in (a) and (b) above will be described.

[0114] A PCR primer set was designed to generate mutant clusters. As PCR primers for introducing the amino acid substitution of N329K, SEQ ID NO: 7 (forward) and 8 (reverse) were used. As PCR primers for introducing the amino acid substitution of E401G, SEQ ID NO: 9 (forward) and SEQ ID NO: 10 (reverse) were used. As PCR primers for introducing the amino acid substitution T426A, SEQ ID NO: 11 (forward) and SEQ ID NO: 12 (reverse) were used. As PCR primers for introducing the amino acid substitution of A461P, SEQ ID NOs: 13 (forward) and 14 (reverse) were used. As PCR primers for introducing the amino acid substitution H389Y, SEQ ID NO: 15 (forward) and 16 (reverse) were used. As PCR primers for introducing the amino acid substitution K(Q)467N, SEQ ID NOs: 17 (forward) and 18 (reverse) were used. As PCR primers for introducing the amino acid substitution V480T, SEQ ID NO: 19 (forward) and 20 (reverse) were used. Each was designed.

[0115] (a) AVR25a This protein was produced by selecting N329K, E401G, T426A, and A461P from the amino acid substitutions involved in alkaline stability identified in Reference Example 1, and introducing these amino acid substitutions into AVR21 (sequence number 2).

[0116] (a-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 7 (5'-AGCTGAAAGTCTACGTACTGCTGGT-3') and SEQ ID NO: 8 (5'-TAGACTTTCAGCTGGGCTTCATGTT-3') as PCR primers to prepare a reaction solution with the composition shown in Table 5. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were performed, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.

[0117] [Table 5]

[0118] (a-2) Using the PCR product obtained in (a-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 9 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 10 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0119] (a-3) Using the PCR product obtained in (a-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 11 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 12 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0120] (a-4) Using the PCR product obtained in (a-3) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 13 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 14 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0121] (a-5) The PCR product obtained in (a-4) was used to transform E. coli BL21 strain (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. The plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR25a containing a polynucleotide encoding AVR25a, which has 25 amino acid substitutions relative to the native AAV binding protein.

[0122] (a-6) The nucleotide sequence of pET-AVR25a was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0123] The amino acid sequence of AVR25a with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 5. In SEQ ID NO: 5, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR25a (corresponding to the region from the 25th to the 213th in SEQ ID NO: 2), and the portion from the 214th to the 219th histidine (H) is the tag sequence. In addition, in SEQ ID NO:5, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 93rd position. In the first place, V381A alanine is at position 94, I382V valine is at position 95, G390S serine is at position 103, K399E glutamic acid is at position 112, E401G glycine is at position 114, T426A alanine is at position 139, A461P proline is at position 174, K467Q glutamine is at position 180, S476R arginine is at position 189, S482T threonine is at position 195, N487D aspartic acid is at position 200, and N492D aspartic acid is at position 205.

[0124] (b) AVR27a This protein was generated by introducing all of the amino acid substitutions described above (N329K, E401G, T426A, A461P, H389Y, K(Q)467N and V480T) into AVR21 (SEQ ID NO:2).

[0125] (b-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 7 (5'-AGCTGAAAGTCTACGTACTGCTGGT-3') and SEQ ID NO: 8 (5'-TAGACTTTCAGCTGGGCTTCATGTT-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were performed, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally a heat treatment at 72°C for 5 minutes.

[0126] (b-2) Using the PCR product obtained in (b-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 9 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 10 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0127] (b-3) Using the PCR product obtained in (b-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 11 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 12 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0128] (b-4) Using the PCR product obtained in (b-3) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 13 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 14 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0129] (b-5) Using the PCR product obtained in (b-4) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 15 (5'-ACGCGTATTCCGAGGGGTATGTTAA-3') and SEQ ID NO: 16 (5'-TCGGAATACGCGTTCTGGCCTTCCA-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally a heat treatment at 72°C for 5 minutes, thereby performing PCR.

[0130] (b-6) Using the PCR product obtained in (b-5) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 17 (5'-TCTCGAATCTGGTACCAGGTAACTA-3') and SEQ ID NO: 18 (5'-ACCAGATTCGAGAGCTTAAGAATGG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally a heat treatment at 72°C for 5 minutes, thereby performing PCR.

[0131] (b-7) Using the PCR product obtained in (b-6) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 19 (5'-CCGTGACCGATACAGATGGTGCGAC-3') and SEQ ID NO: 20 (5'-GTATCGGTCACGGTCAGGCGAAACG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally a heat treatment at 72°C for 5 minutes, thereby performing PCR.

[0132] (b-8) The PCR product obtained in (b-7) was used to transform E. coli BL21 strain (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then centrifuged to recover the transformant. The plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR27a containing a polynucleotide encoding AVR27a, which has 27 amino acid substitutions relative to the native AAV binding protein.

[0133] (b-9) The nucleotide sequence of pET-AVR27a was analyzed and confirmed in a manner similar to that in Reference Example 1(8).

[0134] The amino acid sequence of AVR27a with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 6. In SEQ ID NO: 6, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR27a (corresponding to the region from the 25th to the 213th in SEQ ID NO: 2), and the portion from the 214th to the 219th histidine (H) is the tag sequence. In addition, in SEQ ID NO:6, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, the arginine of K380R is at the 93rd position, and the alanine of V381A is at the 94th position. I382V valine is at position 95, H389Y tyrosine is at position 102, G390S serine is at position 103, K399E glutamic acid is at position 112, E401G glycine is at position 114, T426A alanine is at position 139, A461P proline is at position 174, K(Q)467N asparagine is at position 180, S476R arginine is at position 189, V480T threonine is at position 193, S482T threonine is at position 195, N487D aspartic acid is at position 200, and N492D aspartic acid is at position 205.

[0135] Example 3: Evaluation of alkaline stability of AVR21 amino acid substitution aggregates (1) As transformants capable of expressing AAV binding proteins, the E. coli strain BL21(DE3) was transformed with plasmids containing polynucleotides encoding either one of the two types of AAV binding proteins obtained in Example 2 (AVR25a [SEQ ID NO: 5] and AVR27a [SEQ ID NO: 6]) or AVR21 (SEQ ID NO: 2). The resulting transformants were inoculated into 3 mL of 2xYT liquid medium containing 50 μg / mL kanamycin and pre-cultured overnight at 37°C under aerobic shaking.

[0136] (2) 2 mL of the preculture solution from (1) was inoculated into 200 mL of 2xYT liquid medium containing 50 μg / mL kanamycin in a 1 L baffled flask, and cultured aerobically at 37°C with shaking.

[0137] (3) After 2.0 hours from the start of the culture, the mixture was cooled on ice, IPTG was added to a final concentration of 0.1 mM, and the mixture was subsequently cultured aerobically with shaking at 25°C for 20 hours.

[0138] (4) After the cultivation was completed, the culture solution was centrifuged at 8,000 rpm at 4° C. for 20 minutes to recover each cultured bacterial body (transformant).

[0139] (5) The cells collected in (4) were suspended in equilibration solution A at 5 mL / 1 g (cells), and then disrupted using an ultrasonic generator (Insonator 201M (Kubota Shoji)) at 8°C for about 10 minutes at an output of about 150 W. The disrupted cell solution was centrifuged twice at 8,000 rpm for 20 minutes at 4°C, and each supernatant was collected.

[0140] (6) The supernatant obtained in (5) was applied to an open column packed with 1.5 mL of Ni Sepharose 6 Fast Flow (manufactured by Cytiva) that had been previously equilibrated with equilibration solution A. After washing with equilibration solution A, the column was eluted with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.

[0141] (7) Each eluate obtained in (6) was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride to prepare an AAV-binding protein.

[0142] (8) Using the ELISA method described in Reference Example 1(6), the binding activity of the AAV-binding protein prepared in (7) to the VLP2 prepared in Example 1 was measured. Based on the absorbance at 450 nm, which is the measurement result, the AAV-binding protein obtained in (7) was diluted with pure water so that the measured value became similar.

[0143] (9) Each AAV-binding protein solution diluted in (8) was divided into two fractions. One fraction was mixed with an equal amount of 0.5 M aqueous sodium hydroxide solution and subjected to an alkali treatment by standing at a certain temperature for a certain period of time (treatment temperature: 30°C, treatment time: 0, 30, 60 minutes), while the other fraction was not subjected to the alkali treatment (corresponding to the "start" of the alkali treatment).

[0144] (10) The fraction after treatment in (9) was mixed with 0.5 M MES (2-(N-Morpholino)EthaneSulfonic acid) buffer (pH 6.0) in a ratio of 8:2 to adjust the pH to around 6, and then the binding activity with VLP2 was measured by the ELISA method described in Reference Example 1(6).

[0145] (11) The residual activity was calculated by dividing the absorbance at 450 nm after the alkali treatment in (10) by the absorbance at 450 nm after the treatment time of 0 hours.

[0146] The results are shown in Table 6. It can be seen that the AVR21 amino acid substitution aggregate obtained in Example 2 has higher residual activity and improved alkali stability compared to AVR21 (SEQ ID NO: 2).

[0147] [Table 6]

[0148] Example 4 Construction of AAV vectors The AAV vector used as AAV in the following examples was prepared by the following method.

[0149] (1) A nucleotide sequence (SEQ ID NO: 22) was designed in which a restriction enzyme EcoRI recognition sequence (GAATTC) was added to the 5'-end of a polynucleotide encoding EGFP (Enhanced Green Fluorescent Protein) consisting of the amino acid sequence set forth in SEQ ID NO: 21, and a stop codon (TAG) and a BamHI recognition sequence (GGATTC) were added to the 3'-end.

[0150] (2) A polynucleotide consisting of the sequence set forth in SEQ ID NO:22 was totally synthesized and cloned into a plasmid (entrusted to FASMAC, named pUC-EGFP). E. coli JM109 strain was transformed with pUC-EGFP, and the resulting transformant was cultured. pUC-EGFP was extracted from the culture medium using a QIAprep Spin Miniprep kit (Qiagen).

[0151] (3) The pUC-EGFP obtained in (2) was digested with the restriction enzymes EcoRI and BamHI, and then ligated into the expression vector pAAV-CMV (Takara Bio Inc.) which had been previously digested with the restriction enzymes EcoRI and BamHI. The ligation product was used to transform the Escherichia coli JM109 strain.

[0152] (4) The transformant obtained in (3) was cultured overnight at 37°C with shaking in a 5 L baffled flask containing 1 L of 2xYT medium (1.6% (w / v) Tryptone, 1% (w / v) Yeast Extract, 0.5% (w / v) sodium chloride) containing 100 μg / mL carbenicillin. After the culture was completed, the cells were collected by centrifugation, and pAAV-EGFP was prepared in large quantities from the collected cells using a Plasmid Mega Kit (Qiagen).

[0153] (5) The E. coli JM109 strain was transformed with a plasmid (hereinafter also referred to as "pRC8 Vector") containing a polynucleotide encoding the capsid of serotype 8 (AAV8) and the pHelper Vector (manufactured by Takara Bio Inc.) The obtained transformant was used to carry out the same procedure as in (4) to prepare large quantities of the pRCX Vector and pHelper.

[0154] (6) HEK293T cells were cultured in 10 T-225 flasks (Thermo Fisher Scientific) containing 45 mL of D-MEM medium (Fujifilm Wako Pure Chemical Industries, Ltd.) containing 10% (v / v) bovine serum. The pAAV-EGFP prepared in (4), the pRC8 Vector prepared in (5), and a complex of pHelper and polyethyleneimine (Polysciences) were added thereto for gene transfer, and the cells were statically cultured for 3 days under conditions of 5% (v / v) carbon dioxide and 37°C. After the culture, the cells were detached by centrifugation and collected, and the cells obtained from each of the five T-225 flasks were frozen and stored at -80°C.

[0155] (7) The frozen cells obtained in (6) were thawed and suspended in 10 mL of 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride, 4 mM magnesium chloride, and 0.01% (w / v) Tween 20 (Sigma-Aldrich). Benzonase (Merck Millipore) was added in an amount of 1 / 2000, and the mixture was left to stand at 37°C for 1 hour, and then centrifuged at 13,000 x g and 4°C for 10 minutes to obtain a supernatant. Ammonium sulfate was added to the obtained supernatant to 15% saturation, and centrifuged again under the same conditions. The obtained supernatant was passed through a filter with a pore size of 0.45 μm to remove floating matter.

[0156] (8) The supernatant from which the floating matter had been removed was applied to a 7 mL POROS AAVX column (Thermo Fisher Scientific) that had been equilibrated in advance with 20 mM Tris-HCl buffer (pH 8.0) containing 0.5 M sodium chloride (hereinafter also referred to as "equilibration solution B").

[0157] (9) After washing with equilibration solution B, elution was performed with 0.1 M acetate buffer (pH 2.5) containing 0.5 M sodium chloride. The resulting eluate was neutralized by adding 1 / 4 volume of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride to obtain a solution of the AAV vector, AAV8-EGFP.

[0158] (10) The AAV8-EGFP concentration in the solution obtained in (9) was quantified by qPCR using the AAVpro Titration Kit (Takara Bio Inc.). The solution was subjected to SDS-PAGE and silver stained using the Pierce Silver Stain Kit (Thermo Fisher Scientific Inc.) to confirm the purity of the AAV vector contained in the solution.

[0159] Example 5 Preparation of AAV-binding protein immobilized gel (1) A gel was prepared by chemically modifying the hydroxyl groups on the surface of a hydrophilic vinyl polymer for separation (Tosoh Corporation: Toyopearl) to introduce iodoacetamide groups. 16 mg of the AVR27a protein prepared in Example 4 and TCEP (Tris(2-CarboxyEthyl)Phosphine) at a final concentration of 0.1 mM as a reducing agent were added to 1.0 g of the prepared gel, and the mixture was allowed to react by shaking for 3 hours at pH 7.4 and 25°C. As a result, a gel in which AVR27a was immobilized (named AVR27a-immobilized gel) was prepared.

[0160] (2) The AVR27a immobilized gel prepared in (1) and the commercially available product POROS AAVX (manufactured by Thermo Fisher Scientific) were each packed in approximately 10 μL of a Cosmos Spin Filter G (manufactured by Nacalai Tesque) to prepare two mini-columns (named AVR27a mini-columns and POROS AAVX mini-columns, respectively).

[0161] (3) 90 μL of an aqueous solution containing 0.1 M sodium hydroxide and 1 mM calcium chloride was added to one of the mini-columns and left to stand (soak) for 24 hours. After that, 210 μL of 0.5 M MES buffer (pH 6.0) was added to neutralize it.

[0162] (4) For each mini-column, add 50 mM acetate buffer containing 150 mM sodium chloride. (pH 6.0) (hereinafter also referred to as "equilibration solution C"), the AAV8-EGFP purified product obtained in Example 4 was applied to the flow-through fraction in an amount sufficient to confirm leakage of AAV8-EGFP. The amount of AAV8-EGFP finally applied per column was 6.9 × 10 11 It became VG (Vector Genome).

[0163] (5) To elute and recover the AAV bound to the gel, the column was washed twice with 200 μL of equilibration solution C, and each filtrate was recovered together with the flow-through fraction from (4).

[0164] (6) 200 μL of 50 mM acetate buffer (pH 2.0) containing 500 mM sodium chloride (hereinafter also referred to as "eluent A") was added to each mini-column, and after shaking for 5 minutes, the eluate was collected by centrifugation. 200 μL of eluent A was added to the mini-column again, and after shaking for 1 minute in the same manner, it was centrifuged, and 400 μL was collected together with the previous eluate. Further, 400 μL of eluent A was added, centrifuged, and the eluate was collected (hereinafter also referred to as "Elute 1"). Elute 1 was neutralized by adding 200 μL of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride.

[0165] (7) The number of AAV8-EGFP vector genomes contained in Elute 1 obtained in (6) was quantified by qPCR (quantitative PCR) using the AAVpro Titration Kit (Takara Bio Inc.). For each Elute 1, the amount of AAV bound after immersion in sodium hydroxide for 24 hours was divided by the amount of AAV bound without immersion to calculate the residual activity [%].

[0166] The results are shown in Figure 1. POROS AAVX was unable to capture much AAV, whereas the AVR27a-immobilized gel retained the same amount of AAV bound to it as before immersion in alkaline solution for 24 hours.

[0167] Reference Example 4: Introduction of amino acid substitutions into AAV binding protein AVR25a AVR25a (SEQ ID NO: 5) was selected from the AVR21 amino acid substitution aggregates evaluated for alkaline stability in Example 2, and an AVR21 amino acid substitution aggregate (designated AVR25c) was prepared by introducing the amino acid substitution K467N, which was found to be an amino acid substitution that improves thermal and alkaline stability in Reference Examples 1 and 2, into AVR25a. SEQ ID NOs: 30 (Forward) and 31 (Reverse), respectively, were designed as PCR primers for introducing the amino acid substitution K467N.

[0168] (1) PCR was performed in the same manner as in Example 2(a-1), except that the vector pET-AVR25a capable of expressing a polypeptide containing AVR25a (SEQ ID NO: 7) was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 30 (5'-GAGAGCTTAAGAATGGGGGTATCCTC-3') and SEQ ID NO: 31 (5'-TTCTTAAGCTCTCGAATCTGGTACC-3') were used as PCR primers.

[0169] (2) From the PCR product obtained in (1), a plasmid (expression vector) pET-AVR25c was obtained, which contains a polynucleotide encoding AVR25c, which has 25 amino acid substitutions relative to the native AAV binding protein, in a manner similar to that described in Example 2(a-5).

[0170] (3) The nucleotide sequence of pET-AVR25c was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0171] The amino acid sequence of AVR25c with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 29. In SEQ ID NO: 29, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR25c (corresponding to the region from the 25th to the 213th in SEQ ID NO: 2), and the portion from the 214th to the 219th histidine (H) is the tag sequence. In addition, in SEQ ID NO:29, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 93rd position. In the first place, V381A alanine is at position 94, I382V valine is at position 95, G390S serine is at position 103, K399E glutamic acid is at position 112, E401G glycine is at position 114, T426A alanine is at position 139, A461P proline is at position 174, K467N asparagine is at position 180, S476R arginine is at position 189, S482T threonine is at position 195, N487D aspartic acid is at position 200, and N492D aspartic acid is at position 205.

[0172] Reference Example 5: Preparation and screening of a mutation library for AAV binding protein AVR25c Using the vector pET-AVR25c capable of expressing a polypeptide containing the AAV binding protein AVR25c (sequence number 29) prepared in Reference Example 4 as a template, random mutations were introduced into the polynucleotide portion encoding the protein using error-prone PCR.

[0173] (1) Error-prone PCR was performed in the same manner as described in Reference Example 1(1) except that vector pET-AVR25c capable of expressing a polypeptide containing AVR25c (SEQ ID NO: 29) was used as a template. Mutations were successfully introduced into the polynucleotide encoding the AAV binding protein by the error-prone PCR, with the average mutation introduction rate being 1.8 amino acid mutations per molecule.

[0174] (2) A random mutant library was prepared from the PCR products obtained in (1) by the methods described in Reference Example 1 (2) and (3).

[0175] (3) The random mutant library (transformants) prepared in (2) was inoculated into 200 μL of 2xYT liquid medium containing 50 μg / mL kanamycin, and cultured overnight at 37°C with shaking in a 96-well deep-well plate.

[0176] (4) The culture medium of (3) was centrifuged, and the obtained culture supernatant was diluted 2-fold with ultrapure water. 50 μL of the diluted culture supernatant was mixed with 50 μL of 1 M sodium hydroxide aqueous solution, and then subjected to an alkali treatment at 30° C. for 15 minutes.

[0177] (5) The binding activity of the AAV binding protein to VLP2 when treated with (4) and when not treated with (4) were evaluated by the ELISA method described in Reference Example 1 (6). The binding activity of the AAV binding protein to VLP2 when treated with alkali was divided by the binding activity of the AAV binding protein to VLP2 when not treated with alkali to calculate the residual activity.

[0178] (6) A random mutant library of approximately 1,800 strains was evaluated using the method described in (5), and transformants expressing AAV binding proteins with improved residual activity compared to the parent molecule, AVR25c, were selected.

[0179] (7) The transformant selected in (6) was cultured, and an expression vector was prepared using a QIAprep Spin Miniprep kit (Qiagen). The sequence of the polynucleotide region encoding the AAV binding protein inserted into the vector was then analyzed by the method described in Reference Example 1(8) (subcontracted to FASMAC) to identify the amino acid substitution sites.

[0180] Table 7 shows the amino acid substitution positions relative to AVR25c of the AAV binding proteins expressed by the transformants selected in (7) above, as well as the residual activity [%] after alkali treatment.

[0181] In the amino acid sequence of SEQ ID NO: 2, the amino acid residues from the 25th serine (S) to the 500th aspartic acid (D) are selected from the group consisting of G314D, V(D)317G, Q318R, P322A, E325V, Q347R, T350A, E362D, H363P, I366F, E378G, F(Y)379N, G392E, V394A, V398A, E399K, R406H, Q415R, F4 An AAV binding protein having at least one of the following amino acid substitutions, 16L, L421P, S433G, T434S, D437V, E445K, K455R, S457R, T474R, T478I, A485V, T486A, L493M, N496D, K497E, V499I, or D500G, can be said to have improved alkaline stability compared to AVR25c (sequence number 29).

[0182] [Table 7]

[0183] Reference Example 6 Preparation of AVR25c Amino Acid Substitution Aggregates From the amino acid substitutions involved in improving the alkaline stability of AAV-binding proteins as revealed in Reference Example 5, I366F, V394A, K455R, and K497E were selected, and these amino acid substitutions were accumulated in AVR25c (SEQ ID NO: 29) to further improve the alkaline stability. Specifically, the following two types of AAV-binding proteins (a) and (b) were designed and prepared. (a) An AAV binding protein in which the amino acid substitutions I366F, V394A, and K455R were introduced into AVR25c (SEQ ID NO: 32, designated AVR28). (b) An AAV binding protein having the amino acid substitutions I366F, V394A, K455R, and K497E introduced into AVR25c (SEQ ID NO: 33, designated AVR29c) Methods for producing the two types of AAV binding proteins shown in (a) and (b) above are described below.

[0184] A PCR primer set was designed to generate mutant clusters. As PCR primers for introducing the amino acid substitution K497E, SEQ ID NO: 34 (Forward) and 35 (Reverse) were used. Designed it.

[0185] (a)AVR28 For this protein, I366F, V394A, and K455R were selected from the amino acid substitutions involved in alkaline stability that were revealed in Reference Example 5. Note that this protein was already obtained in Reference Example 5 (see Table 7), so this was used.

[0186] The amino acid sequence of AVR28 with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 32. In SEQ ID NO: 32, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR28 (corresponding to the region from the 25th to the 213th in SEQ ID NO: 2), and the portion from the 214th to the 219th histidine (H) is the tag sequence. In addition, in SEQ ID NO:32, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the phenylalanine of I366F is at the 79th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, the arginine of K380R is at the 93rd position, and the arginine of V381A is at the 84th position. alanine at position 94, valine at position 95, serine at position G390S, alanine at position 103, alanine at position V394A, glutamic acid at position K399E, glycine at position E401G, glycine at position 114, alanine at position T426A, arginine at position K455R, proline at position A461P, asparagine at position K467N, arginine at position S476R, threonine at position S482T, threonine at position 195, aspartic acid at position N487D, and aspartic acid at position N492D.

[0187] (b) AVR29c This protein was produced by selecting K497E from the amino acid substitutions involved in alkaline stability revealed in Reference Example 5 and introducing this amino acid substitution into AVR28 (sequence number 32).

[0188] (b-1) A reaction solution having the composition shown in Table 8 was prepared using a vector capable of expressing a polypeptide containing AVR28 (SEQ ID NO: 32) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 34 (5'-TTAACGAAGCCGTCGACCATCATCA-3') and SEQ ID NO: 35 (5'-ACGGCTTCGTTAACGGTCAAGTCTG-3') as PCR primers. The reaction solution was then heat-treated at 98°C for 5 minutes, and PCR was performed by performing 30 cycles of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes as one cycle, and finally heat-treating at 72°C for 5 minutes.

[0189] [Table 8]

[0190] (b-2) The PCR product obtained in (b-1) was treated with DpnI (New England Biolabs) to digest the template strand, and the PCR product was used to transform E. coli BL21 strain (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the plasmid was extracted from the bacterial cells (transformant) recovered by centrifugation to obtain a plasmid (expression vector) pET-AVR29c containing a polynucleotide encoding AVR29c with 29 amino acid substitutions relative to the native AAV binding protein.

[0191] (b-3) The nucleotide sequence of pET-AVR29c was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0192] The amino acid sequence of AVR29c with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 33. In SEQ ID NO: 33, the portion from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the portion from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein AVR29c (corresponding to the region from the 25th to the 213th in SEQ ID NO: 2), and the portion from the 214th to the 219th histidine (H) is the tag sequence. In addition, in SEQ ID NO:33, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the phenylalanine of I366F is at the 79th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, the arginine of K380R is at the 93rd position, and the alanine of V381A is at the 94th position. In the 139th position, the valine in I382V is at position 95, the serine in G390S is at position 103, the alanine in V394A is at position 107, the glutamic acid in K399E is at position 112, the glycine in E401G is at position 114, the alanine in T426A is at position 139, the arginine in K455R is at position 168, the proline in A461P is at position 174, the asparagine in K467N is at position 180, the arginine in S476R is at position 189, the threonine in S482T is at position 195, the aspartic acid in N487D is at position 200, the aspartic acid in N492D is at position 205, and the glutamic acid in K497E is at position 210.

[0193] Reference Example 7 Preparation of AAV binding protein with signal peptide sequence removed (1) PCR was performed in the same manner as in Reference Example 6(b-1), except that pET-AVR29c prepared in Reference Example 6(b) was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 36 (5'-ACATATGTCTGCAGGCGAAAGCGAC-3') and SEQ ID NO: 37 (5'-CCTGCAGACATATGTATATCTCCTTC-3') were used as PCR primers.

[0194] (2) From the PCR product obtained in (1), a plasmid (expression vector) pET-AVR29c(-) was obtained using a method similar to that of Reference Example 6(b-2), which encodes AVR29c, which has 29 amino acid substitutions relative to the native AAV binding protein, and contains a polynucleotide that does not have a signal sequence on the N-terminus.

[0195] (3) The nucleotide sequence of pET-AVR29c(-) was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0196] The amino acid sequence of AVR29c(-) with a polyhistidine tag added is shown in SEQ ID NO: 38. In SEQ ID NO: 38, the sequence from the second serine (S) to the 190th aspartic acid (D) represents the AAV binding protein AVR29c (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the sequence from the 191st to 196th histidines (H) represents the tag sequence. In addition, in SEQ ID NO:38, the aspartic acid of V317D is at the 7th position, the histidine of N324H is at the 14th position, the alanine of V326A is at the 16th position, the lysine of N329K is at the 19th position, the valine of A330V is at the 20th position, the leucine of Q334L is at the 24th position, the valine of E335V is at the 25th position, the alanine of T341A is at the 31st position, the serine of Y342S is at the 32nd position, the glutamic acid of K362E is at the 52nd position, the phenylalanine of I366F is at the 56th position, the asparagine of K371N is at the 61st position, the tyrosine of F379Y is at the 69th position, the arginine of K380R is at the 70th position, and the alanine of V381A is at the 71st position. 3, valine at position 72, serine at position 80, alanine at position 84, glutamic acid at position 89, glycine at position 91, alanine at position 116, arginine at position 145, proline at position 151, asparagine at position 157, arginine at position 166, threonine at position 172, aspartic acid at position 177, aspartic acid at position 182, and glutamic acid at position 187.

[0197] Example 6 Preparation of AVR29c(-) amino acid substitution aggregate An AAV-binding protein was prepared by introducing H389Y and / or V480T, which are the amino acid substitutions involved in improving stability, into the AAV-binding protein AVR29c(-) (corresponding to the region from the 2nd to the 190th in SEQ ID NO: 38) prepared in Reference Example 7. Specifically, the following three types of AAV-binding proteins (a), (b), and (c) were designed and prepared. (a) AAV binding protein in which the amino acid substitution V480T was introduced into AVR29c(-) (SEQ ID NO: 43, named AVR30a(-)) (b) AAV binding protein in which the amino acid substitution H389Y was introduced into AVR29c(-) (SEQ ID NO: 44, designated AVR30b(-)) (c) AAV binding protein in which amino acid substitutions H389Y and V480T were introduced into AVR29c(-) (SEQ ID NO: 45, designated AVR31b(-)) Methods for producing the three types of AAV binding proteins shown in (a), (b) and (c) above are described below.

[0198] A PCR primer set was designed to generate mutant clusters. As PCR primers for introducing the amino acid substitution H389Y, SEQ ID NO: 39 (Forward) and 40 (Reverse) were used. As PCR primers for introducing the amino acid substitution V480T, SEQ ID NO: 41 (Forward) and 42 (Reverse) were used. Each was designed.

[0199] (a) AVR30a(-) (a-1) PCR was performed in the same manner as in Reference Example 6 (b-1), except that pET-AVR29c(-) prepared in Reference Example 7 was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 41 (5'-CGGTGACCGACACCGACGGGGCAAC-3') and SEQ ID NO: 42 (5'-GTGTCGGTCACCGTTAAGCGAAAAG-3') were used as PCR primers.

[0200] (a-2) From the PCR product obtained in (a-1), a plasmid (expression vector) pET-AVR30a(-) containing a polynucleotide encoding AVR30a(-), which has 30 amino acid substitutions relative to the native AAV binding protein, was obtained in a manner similar to that of Reference Example 6(b-2).

[0201] (a-3) The nucleotide sequence of pET-AVR30a(-) was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0202] The amino acid sequence of AVR30a(-) with a polyhistidine tag added is shown in SEQ ID NO: 43. In SEQ ID NO: 43, the portion from the second serine (S) to the 190th aspartic acid (D) represents the AAV binding protein AVR30a (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the 191st to 196th histidines (H) represent the tag sequence. In addition, in SEQ ID NO: 43, the aspartic acid of V317D is at the 7th position, the histidine of N324H is at the 14th position, the alanine of V326A is at the 16th position, the lysine of N329K is at the 19th position, the valine of A330V is at the 20th position, the leucine of Q334L is at the 24th position, the valine of E335V is at the 25th position, the alanine of T341A is at the 31st position, the serine of Y342S is at the 32nd position, the glutamic acid of K362E is at the 52nd position, the phenylalanine of I366F is at the 56th position, the asparagine of K371N is at the 61st position, the tyrosine of F379Y is at the 69th position, the arginine of K380R is at the 70th position, the alanine of V381A is at the 71st position, and the alanine of I382V is at the 72nd position. Valine is at position 72, serine at position 80, alanine at position 84, glutamic acid at position 89, glycine at position 91, alanine at position 116, arginine at position 145, proline at position 151, asparagine at position 157, arginine at position 166, threonine at position 170, threonine at position 172, aspartic acid at position 177, aspartic acid at position 182, and glutamic acid at position 187.

[0203] (b) AVR30b(-) (b-1) PCR was performed in the same manner as in (a-1) except that oligonucleotides consisting of the sequences set forth in SEQ ID NO: 39 (5'-ATGCTTATTCAGAGGGCTATGCCAAC-3') and SEQ ID NO: 40 (5'-TCTGAATAAGCATTTTGGCCCTCCAC-3') were used as PCR primers.

[0204] (b-2) From the PCR product obtained in (b-1), a plasmid (expression vector) pET-AVR30b(-) containing a polynucleotide encoding AVR30b(-), which has 30 amino acid substitutions relative to the native AAV binding protein, was obtained in a manner similar to that of Reference Example 6(b-2).

[0205] (b-3) The nucleotide sequence of pET-AVR30b(-) was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0206] The amino acid sequence of AVR30b(-) with a polyhistidine tag added is shown in SEQ ID NO: 44. In SEQ ID NO: 44, the portion from the second serine (S) to the 190th aspartic acid (D) represents the AAV binding protein AVR30b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the 191st to 196th histidines (H) represent the tag sequence. In addition, in SEQ ID NO: 44, the aspartic acid of V317D is at the 7th position, the histidine of N324H is at the 14th position, the alanine of V326A is at the 16th position, the lysine of N329K is at the 19th position, the valine of A330V is at the 20th position, the leucine of Q334L is at the 24th position, the valine of E335V is at the 25th position, the alanine of T341A is at the 31st position, the serine of Y342S is at the 32nd position, the glutamic acid of K362E is at the 52nd position, the phenylalanine of I366F is at the 56th position, the asparagine of K371N is at the 61st position, the tyrosine of F379Y is at the 69th position, the arginine of K380R is at the 70th position, the alanine of V381A is at the 71st position, and the alanine of I382V is at the 72nd position. valine at position 72, H389Y tyrosine at position 79, G390S serine at position 80, V394A alanine at position 84, K399E glutamic acid at position 89, E401G glycine at position 91, T426A alanine at position 116, K455R arginine at position 145, A461P proline at position 151, K467N asparagine at position 157, S476R arginine at position 166, S482T threonine at position 172, N487D aspartic acid at position 177, N492D aspartic acid at position 182, and K497E glutamic acid at position 187.

[0207] (c) AVR31b(-) This protein was generated by introducing the V480T amino acid substitution into AVR30b(-) (SEQ ID NO: 44).

[0208] (c-1) PCR was performed in the same manner as in (a-1) except that pET-AVR30b(-) prepared in (b) was used as a template.

[0209] (c-2) From the PCR product obtained in (c-1), a plasmid (expression vector) pET-AVR31b(-) containing a polynucleotide encoding AVR31b(-), which has 31 amino acid substitutions relative to the native AAV binding protein, was obtained in a manner similar to that of Reference Example 6(b-2).

[0210] (c-3) The nucleotide sequence of pET-AVR31b(-) was analyzed and confirmed in a manner similar to that described in Reference Example 1(8).

[0211] The amino acid sequence of AVR31b(-) with a polyhistidine tag added is shown in SEQ ID NO: 45. In SEQ ID NO: 45, the sequence from the second serine (S) to the 190th aspartic acid (D) represents the AAV binding protein AVR31b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the sequence from the 191st to 196th histidines (H) represents the tag sequence. In addition, in SEQ ID NO: 45, the aspartic acid of V317D is at the 7th position, the histidine of N324H is at the 14th position, the alanine of V326A is at the 16th position, the lysine of N329K is at the 19th position, the valine of A330V is at the 20th position, the leucine of Q334L is at the 24th position, the valine of E335V is at the 25th position, the alanine of T341A is at the 31st position, the serine of Y342S is at the 32nd position, the glutamic acid of K362E is at the 52nd position, the phenylalanine of I366F is at the 56th position, the asparagine of K371N is at the 61st position, the tyrosine of F379Y is at the 69th position, the arginine of K380R is at the 70th position, the alanine of V381A is at the 71st position, and the valine of I382V is at the 72nd position. In the present study, the tyrosine of H389Y is at position 79, the serine of G390S is at position 80, the alanine of V394A is at position 84, the glutamic acid of K399E is at position 89, the glycine of E401G is at position 91, the alanine of T426A is at position 116, the arginine of K455R is at position 145, the proline of A461P is at position 151, the asparagine of K467N is at position 157, the arginine of S476R is at position 166, the threonine of V480T is at position 170, the threonine of S482T is at position 172, the aspartic acid of N487D is at position 177, the aspartic acid of N492D is at position 182, and the glutamic acid of K497E is at position 187.

[0212] Example 7: Evaluation of alkaline stability of amino acid substituted aggregates (1) As transformants capable of expressing AAV-binding proteins, transformants obtained by transforming Escherichia coli strain BL21(DE3) with a plasmid containing a polynucleotide encoding AVR29c(-) (SEQ ID NO: 38) obtained in Reference Example 7, or any of the three types of AAV-binding proteins obtained in Example 6 (AVR29c(-) amino acid substitution aggregates, specifically AVR30a(-) (SEQ ID NO: 43), AVR30b(-) (SEQ ID NO: 44), and AVR31b(-) (SEQ ID NO: 45)) were used. The transformants were cultured in the same manner as in Example 3(1) to (4), and the bacterial cells (transformants) were recovered.

[0213] (2) The cells collected in (1) were disrupted by the method described in Example 3(5), the supernatant was collected, and the AAV binding protein was prepared by the methods described in Example 3(6) to (7).

[0214] (3) Using the ELISA method described in Reference Example 1(6), the binding activity between the AAV-binding protein prepared in (2) and the VLP2 prepared in Example 1 was measured. The concentration of the AAV-binding protein solution prepared in (2) was measured using NanoDrop OneC (Thermo Fisher Scientific), and then diluted with 20 mM Tris-HCl buffer (pH 7.4) to a protein concentration of 5 μg / mL.

[0215] (4) Each AAV-binding protein solution diluted in (3) was mixed with an equal amount of 1 M aqueous sodium hydroxide solution containing 1 mM calcium chloride, and subjected to alkaline treatment by leaving the solution at a constant temperature for a certain period of time (treatment temperature: 30°C, treatment time: 0, 20, 30 minutes).

[0216] (5) The fraction after treatment in (4) was mixed with 0.5 M MES buffer (pH 6.0) in a ratio of 8:2 to adjust the pH to around 6, and then the binding activity with VLP2 was measured using the ELISA method described in Reference Example 1 (6).

[0217] (6) The residual activity was calculated by dividing the absorbance at 450 nm after the alkali treatment in (5) by the absorbance at 450 nm when the treatment time was 0 minutes.

[0218] The results are shown in Table 9. It can be seen that the AVR29c(-) amino acid substitution aggregate obtained in Example 6 has higher residual activity and improved alkali stability compared to AVR29c(-) (SEQ ID NO: 38).

[0219] [Table 9]

Claims

1. An AAV binding protein selected from any of the following (i) to (iii): (i) at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 2, provided that the amino acid residues from the 25th to the 213th At least one of the following amino acid residues (1) to (2) an AAV binding protein in which amino acid substitutions have been made and which has AAV binding activity; (1) Substitution of histidine at position 102 of SEQ ID NO:2 with tyrosine (2) Substitution of valine at position 193 of SEQ ID NO:2 with threonine (ii) an AAV binding protein comprising at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 2, with at least one of the amino acid substitutions (1) to (2) occurring in the amino acid residues from the 25th to the 213th, and further comprising any one or more of substitutions, deletions, insertions, and additions of one or several amino acid residues at one or several positions other than the amino acid substitutions shown in (1) to (2), and having AAV binding activity; (iii) An AAV binding protein comprising an amino acid sequence from the 25th serine to the 213th aspartic acid of the amino acid sequence set forth in SEQ ID NO: 2, which has an identity of 70% or more to the entire amino acid sequence in which at least one of the amino acid substitutions (1) to (2) has occurred, and in which the at least one amino acid substitution remains, and which has AAV binding activity.

2. The AAV binding protein according to claim 1, further comprising at least one amino acid substitution as shown in the following (3): (3) Substitution of glutamine at position 180 of SEQ ID NO:2 with asparagine

3. The AAV binding protein according to claim 2, which comprises at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO: 2, with the proviso that at least any of the amino acid substitutions shown in (A) to (D) below occurs in the amino acid residues from the 25th to the 213th, and has AAV binding activity; (A) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, histidine at position 102 of SEQ ID NO:2 is substituted with tyrosine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and valine at position 193 of SEQ ID NO:2 is substituted with threonine. (B) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, valine at position 193 of SEQ ID NO:2 is substituted with threonine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (C) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, histidine at position 102 of SEQ ID NO:2 is substituted with tyrosine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (D) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, histidine at position 102 of SEQ ID NO:2 is substituted with tyrosine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, valine at position 193 of SEQ ID NO:2 is substituted with threonine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid.

4. A polynucleotide encoding an AAV binding protein according to any one of claims 1 to 3.

5. An expression vector comprising the polynucleotide of claim 4.

6. A transformant obtained by transforming Escherichia coli with the expression vector according to claim 5.

7. A method for producing an AAV binding protein, comprising the steps of expressing the AAV binding protein by culturing the transformant described in claim 6, and recovering the expressed AAV binding protein from the resulting culture.

8. An AAV adsorbent comprising an insoluble carrier and an AAV binding protein according to any one of claims 1 to 3 immobilized on the carrier.

9. A column comprising the AAV adsorbent of claim 8.

10. A method for purifying or analyzing AAV, comprising the steps of adding a solution containing AAV to the column described in claim 9 to adsorb the AAV to the adsorbent, and eluting the AAV adsorbed to the adsorbent using an elution solution.

11. The method for purifying or analyzing AAV described in claim 10, further comprising a step of washing the AAV adsorbent with an alkaline solution after the step of eluting AAV.

Citation Information

Patent Citations

  • Improved adeno-associated virus-binding protein, method for producing same, and adeno-associated virus adsorbent using same

    WO2021106882A1